1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62BA139546D9E69E285257EF800767EC9
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-enabling-marketing-insights-superior-competitiveness-faster-market-research-approvals-lessons-learned-roles-responsibilities?opendocument
18
19opendocument
2018.204.56.104
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Market Research, Analytics and Forecasting Process Excellence and Productivity Management

Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals: Lessons Learned and Roles & Responsibilities

ID: 5387


Features:

17 Info Graphics

7 Data Graphics

65 Metrics

17 Narratives


Pages/Slides: 35


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals: Lessons Learned and Roles & Responsibilities"

STUDY OVERVIEW

In the fast pace of today's marketplace, pharmaceutical companies need to be able to make strategic decisions quickly to maintain or gain a competitive advantage. This is especially true when it comes to making decisions based on internal market research studies. Having a laborious internal review process for these market research projects can bog down a study's launch and, consequently, slow down decisions. Therefore, it behooves organizations to adopt an efficient approach to the market research approval process.


Best Practices, LLC undertook this benchmarking study to provide qualitative and quantitative data on how leading companies manage roles and responsibilities to expedite the market research approval process. The study also provides a healthy sample of qualitative insights from participants that deal with lessons learned in speeding up the review of market research study proposals. Using both metrics and insights to create process slides that outline effective approaches to this topic, the study provides an overview of how companies are addressing this issue.



KEY TOPICS

  • Best Practices of High-Performing Companies
  • Managing Roles & Responsibilities
  • Lessons Learned & Pitfalls to Avoid
  • Path Forward Recommendations


KEY METRICS
  • Legal or Compliance Review Required for Eight Market Research Study Types
  • Review Requirements for Major Country Markets
  • Share Top Lessons Learned for Creating High Performing Market Research Approval Process

SAMPLE KEY FINDINGS
  • Collaboration: Develop a solution-oriented collaborative culture across groups. Invite unit heads to address other groups. Use education to inform groups about other groups’ needs and requirements. Forty percent of companies highly prefer in-person meetings to create collaborative teams.

METHODOLOGY

Best practices, LLC engaged 22 executives from 21 leading pharmaceutical, biotech, and life sciences companies. Eleven companies responded on behalf of rare disease markets. Eight companies participated in deep-dive interviews about the drivers of operational excellence.


Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Technology; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbvie; actavis; Amgen; AstraZeneca; Bayer; Biogen; Boehringer Ingelheim; CSL Behring; Fresenius Kabi; Genentech; Grifols; Jazz Pharmaceuticals; Lilly; NeedleTech Products Inc.; Novartis; Novo Nordisk; Philips Healthcare; Roche; Sanofi; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.